Form 8-K - Current report:
SEC Accession No. 0000950170-24-122426
Filing Date
2024-11-06
Accepted
2024-11-06 16:46:38
Documents
12
Period of Report
2024-10-31
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K virx-20241031.htm   iXBRL 8-K 47514
2 EX-99.1 virx-ex99_1.htm EX-99.1 16321
  Complete submission text file 0000950170-24-122426.txt   180676

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT virx-20241031.xsd EX-101.SCH 23863
15 EXTRACTED XBRL INSTANCE DOCUMENT virx-20241031_htm.xml XML 4543
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

EIN.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51531 | Film No.: 241431791
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)